There are currently 18 clinical trials in Oxnard, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Ventura County Hematology Oncology Specialists, Pacific Neuroscience Medical Group, GSK Investigational Site and California Retina Consultants. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
Gender:
All
Ages:
50 years and above
Trial Updated:
02/15/2024
Locations: California Retina Consultants, Oxnard, California
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: PMK Medical Group Inc, Oxnard, California
Conditions: Non Small Cell Lung Cancer
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
Recruiting
A prospective, randomized, double-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to sham
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2024
Locations: EyePoint Investigative Site, Oxnard, California
Conditions: Nonproliferative Diabetic Retinopathy
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: Ventura County Hematology Oncology Specialists, Oxnard, California
Conditions: Breast Cancer
Real-World Experience - Barostimâ„¢ Advancing the Level of Clinical Evidence (REBALANCE Registry)
Recruiting
The purpose of this registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients with heart failure with reduced ejection fraction (HFrEF) that were recently implanted with the Barostim System.
Gender:
All
Ages:
All
Trial Updated:
01/21/2023
Locations: Cabrillo Cardiology Research Group, Oxnard, California
Conditions: Heart Failure
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Ventura County Hematology Oncology Specialists, Oxnard, California
Conditions: Breast Cancer